WHOOP has opened Advanced Labs, its blood testing product, to people who do not own a WHOOP. The tests are drawn at Quest locations, reviewed by a clinician and returned with AI-generated guidance, and no membership is required. Alongside it sits Galleri, GRAIL's blood test that screens a single draw for a signal shared by more than 50 cancer types, and it too can be bought without a subscription or any prior Advanced Labs test.
Reported pricing puts Advanced Labs from around $199 for a single annual test, scaling to $899 for six, against roughly 65 biomarkers. Galleri is reported at $799, one-time, recommended annually and HSA/FSA eligible. Those figures come from third-party comparison sites rather than WHOOP, whose own press pages we could not reach directly, and the biomarker count varies by source. Treat them as indicative.
The same week, a much smaller company made structurally the same move. Mvmnt launched in 2023 as a Sky joint venture, exclusive to Sky Live, a camera that sat on top of a television. Today its form-tracking and rep-counting runs on a phone you already own, at £12.99 a month, with a free tier underneath it. The camera that used to gate the product is gone.
What happens to a gym's longevity upsell when a wearable company sells bloodwork directly?
It acquires a national competitor that does not need the gym in the transaction. A member curious about their metabolic or cardiovascular markers can now buy a clinician-reviewed panel for around $199 without owning any hardware, walking into a facility, or asking a trainer. The gym's advantage was never the test itself. It was proximity and trust, and those are now the only parts of the offer that a direct-to-consumer channel cannot replicate.
| Product | What used to gate it | What gates it now |
|---|---|---|
| WHOOP diagnostics | A WHOOP membership and the strap | About $199, no membership |
| Galleri screening | Physician-led channels | $799, no prior test required |
| Mvmnt form tracking | A Sky Live camera on a TV | Any phone, £12.99 a month |
This is the thesis we have been building for two months, arriving faster than expected. In July we argued that Garmin did not kill WHOOP, it killed the hardware margin, and that once sensors are commodities the interpretation layer is what survives. A week earlier, looking at Eli Lilly's stake in Oura, we wrote that interpretation was the last unowned layer and that studios had never actually won it. WHOOP has now stopped pretending the strap is the business. It is selling interpretation to people who own no WHOOP hardware at all.
The Galleri timing deserves a flag
Galleri is a MCED (multi-cancer early detection) test, and its regulatory status needs stating precisely rather than left to inference. It has been sold since 2021 as a laboratory developed test under CLIA certification. It received FDA breakthrough device designation in 2018. GRAIL submitted the final module of its premarket approval application on January 29 2026, and an FDA advisory committee is scheduled to review that application on September 23 2026. As of today it is not FDA cleared or approved.
So a consumer wearable brand is putting a cancer screening test into a retail funnel roughly five weeks before a federal advisory committee sits down to assess it. That may resolve well. It is still worth naming, particularly for any operator considering a referral relationship in this category.
One more number needs a hedge. WHOOP's founder said that 8 in 10 users report discovering a meaningful health finding. That is self-reported, from the company selling the test, with no published sample size, method, or definition of "meaningful". It is the same pattern we flagged in July, when every source in a batch turned out to be a vendor sales asset. Useful as a marketing claim to be aware of. Not a number to plan against.
What operators should actually do
First, stop treating diagnostics as a future upsell. In August we wrote that a $599 clinical genome was about to change what members expect, and that the window to partner in was closing. The window is closing faster than that piece assumed, and the competitor is now a brand your members already follow.
Second, compete where the direct channel is weak. A blood panel bought online arrives as a PDF and a set of numbers. What it does not come with is somebody who knows the member, sees them three times a week, and can turn a marker into a change in what they do on Tuesday. Trust and proximity are the position, which is the argument we made when the FDA opened up the peptide menu: refer rather than sell, and let the relationship be the product.
Third, watch the Mvmnt detail, because it aims at something more operators are exposed to than they realise. RepCon, its competition format, is built on what it calls high-quality reps as the mechanic rather than heart rate. A great deal of group fitness programming, and a great deal of the wearable integration sitting on top of it, is built on heart-rate zones as the proxy for effort. A phone camera that scores movement quality instead is a different claim about what counts as a good workout, and it is available at £12.99 a month.
The pattern underneath all three moves is the same. For a decade the fitness industry assumed the hardware was the barrier to entry. It was the price of admission, and admission is getting cheaper every quarter.